Movement disorder

Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Bristol Myers Squibb, Patient, Doctor of Philosophy, AIMS, BARS, BMY, Akathisia, Head, Safety, SAS, MD, EPS, Circulatory system, Incidence, KarXT, Extrapyramidal symptoms, Abstract, Society, ASCP, Research, BMS, Aes, Movement disorder, Annual general meeting, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 28-31, 2024 in Miami, FL.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 28-31, 2024 in Miami, FL.
  • “The presentation of additional data from the EMERGENT program continues to illustrate the potential of KarXT as a novel treatment for schizophrenia, with its differentiated mechanism of action and safety and efficacy profile,” said Alyssa Johnsen, MD, PhD , senior vice president and head of clinical development, Immunology, Cardiovascular and Neuroscience, Bristol Myers Squibb.
  • Initial findings showed participants perceived an improvement in positive, negative, and cognitive symptoms of schizophrenia since initiating KarXT.
  • Complete abstracts may be accessed online here , and a full overview of abstracts to be presented at ASCP by BMS can be found below.

PhotoPharmics Enrolls First 25 Patients in Pivotal Parkinson’s Disease Study to Improve Symptoms Beyond the Current Standard of Care

Retrieved on: 
月曜日, 5月 13, 2024
Research, Medical Devices, Neurology, FDA, Clinical Trials, Telemedicine, Virtual Medicine, Biotechnology, General Health, Health, Science, Steps, Patient, Eating, Parkinson's disease, Clinical trial, University, Depression, Light, Travel, Sleep, Disease, Anxiety, Eye, Savage, Seasonal affective disorder, Fatigue, Chet, Therapy, Movement disorder, Telehealth, Quality of life, Cognition, Empowerment, Pharmaceutical industry

This passive, non-invasive therapy complements current medical care, and requires no alteration to existing medical regimens.

Key Points: 
  • This passive, non-invasive therapy complements current medical care, and requires no alteration to existing medical regimens.
  • By addressing PD's underlying mechanisms, it aims to provide a holistic approach to symptomatic improvement and potential disease modification.
  • The disease is progressive, with symptoms worsening over time, leading to an aggravating effect on patients' lives.
  • The company aims to make a clinically meaningful difference in patients’ lives by delivering safe and effective treatments.

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

Retrieved on: 
月曜日, 5月 6, 2024
Frustration, Tardive dyskinesia, Neurocrine Biosciences, Risk, Mental Health Awareness Month, Neurocrine, Bipolar disorder, DSM-IV codes, Somatic symptom disorder, Schizophrenia, Policy, Mental health, Patient, Movement disorder, Diagnosis, MBC, Mental, SAN, Nursing

SAN DIEGO, May 6, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during Tardive Dyskinesia Awareness Week, May 5-11.

Key Points: 
  • SAN DIEGO, May 6, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during Tardive Dyskinesia Awareness Week, May 5-11.
  • "TD Awareness Week increases dialogue around the physical, social and emotional consequences the uncontrollable movements of TD can have on individuals who are trying to manage their mental health," said Josie Cooper, Executive Director of the Movement Disorders Policy Coalition.
  • "We are committed to partnering with all stakeholders during TD Awareness Week and beyond to advocate for routine screenings for patients at risk for TD."
  • To learn more about TD, living with TD and how to treat TD, visit TalkAboutTD.com .

Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project

Retrieved on: 
金曜日, 4月 26, 2024
Spasticity, Bacteriology, WARF, University, Dystonia, Publication, Partnership, Research, AB toxin, Hannover Medical School, Movement disorder, Professional, Acquisition, Jan Vansina, Hyperhidrosis, Migraine, Wisconsin Alumni Research Foundation, Canning

SEOUL, KOREA, April 26, 2024 (GLOBE NEWSWIRE) -- Dr. Eric A. Johnson and Professor Dirk Dressler, internationally renowned botulinum toxin experts, visited South Korea in March this year to join WizMedi Bio's new botulinum toxin development project.

Key Points: 
  • SEOUL, KOREA, April 26, 2024 (GLOBE NEWSWIRE) -- Dr. Eric A. Johnson and Professor Dirk Dressler, internationally renowned botulinum toxin experts, visited South Korea in March this year to join WizMedi Bio's new botulinum toxin development project.
  • The long-standing collaboration between Dr. Johnson and Professor Dressler has shaped the global botulinum toxin landscape over the past decades.
  • Dr. Johnson, a retired professor of bacteriology at the University of Wisconsin-Madison in the US, has dedicated over four decades to botulinum toxin research, authoring over 200 publications and founded 3 botulinum toxin companies.
  • Having introduced most of the major botulinum toxin drugs to the international markets, he is a highly sought-after consultant to the botulinum toxin industry.

Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
金曜日, 4月 12, 2024
Real-World Evidence, Continuity, American Academy, University, FAAN, Parkinson's disease, Randomness, State university system, Abstract, Research, Spirometry, MDT, ALS, Movement disorder, AAN, Disease, MTPA, Control, Data mart, Boundless, Annual general meeting, ISR, University of Cincinnati, Session 9, Knowledge, Pharmaceutical industry

JERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024.

Key Points: 
  • JERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024.
  • The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).
  • Data from the BouNDless subgroup analysis will be presented orally during a Scientific Platform Session at the meeting.
  • ; State University of New York Upstate Medical University)
    Poster Session 6 (#11-013): 8:00 – 9:00 a.m. MDT, April 16

European Parliament Recognizes Essential Tremor as Official Disease in Ground-Breaking Declaration

Retrieved on: 
火曜日, 4月 9, 2024
European Parliament, Myenteric plexus, Movement disorder, Environment, Disease, Social justice, Patient, DSM-IV codes, Joint Declaration, Hope, Quality of life, Parliament, Essential tremor, European, Geography, Insightec, Pharmaceutical industry

BRUSSELS, April 9, 2024 /PRNewswire/ -- The European Parliament, in collaboration with Insightec and patient advocacy groups, has taken a historic step forward in the healthcare realm by signing a Joint Declaration to officially recognize essential tremor as a disease. This monumental move promises to enhance the lives of millions who suffer from the most common movement disorder worldwide, affecting an estimated 54 million people.

Key Points: 
  • The Joint Declaration specifically calls for the following:
    The formal recognition of essential tremor as a distinct disease.
  • "Access to treatment options for essential tremor is a matter of equality and social justice," echoes Maarit Matjussi, chair of ScanShakers and chairwoman of the Finnish Essential Tremor Association.
  • "Signing this Joint Declaration, together with Members of the European Parliament and patient associations across Europe, is a pivotal milestone for Insightec and for people living with essential tremor across Europe.
  • Members of the European Parliament, Insightec, and patient groups are united in their commitment to ensuring equal therapy access and improving quality of life for all affected by this disease.

DrTalks Set to Launch The Parkinson's Solutions Summit 2.0 from November 5 - 11, 2024

Retrieved on: 
木曜日, 4月 4, 2024
Neurology, Health, Disease, Caregiver, Patient, Knowledge, Research, University, Hope, Parkinson's disease, DSM-IV codes, Alzheimer's disease, MPH, Meditation, Hospital, Movement disorder, Tourism

CARLSBAD, Calif., April 4, 2024 /PRNewswire/ -- DrTalks, a leading platform dedicated to advancing health, wellness, and medicine education, is set to launch The Parkinson's Solutions Summit 2.0. This groundbreaking virtual event, happening from November 5 to 11, 2024, offers participants insights into holistic management strategies and treatment options from renowned neurologists and dozens of experts in related fields.

Key Points: 
  • Open to everyone and free of charge, this summit makes vital knowledge accessible to everyone seeking real solutions to regain control of their lives.
  • CARLSBAD, Calif., April 4, 2024 /PRNewswire/ -- DrTalks , a leading platform dedicated to advancing health, wellness, and medicine education, is set to launch The Parkinson's Solutions Summit 2.0 .
  • The Parkinson's Solutions Summit 2.0 will feature various topics, including advanced tests, optimal lifestyle changes, and other holistic strategies to prevent or manage the condition.
  • It will be hosted by two of the most recognizable experts in neurology: Kenneth Sharlin, MD , and Barbara Pickut, MD, MPH .

QuantalX Secures Spot in FDA's Prestigious Total Life Cycle Advisory Program (TAP)

Retrieved on: 
木曜日, 4月 4, 2024
Diagnosis, NPH, Movement disorder, Growth, Cerebrospinal fluid, CSF, Risk, Patient, DSM-IV codes, Stroke, TAP, Doctor of Philosophy, Medtronic, Science, Approximation error, Normal pressure hydrocephalus, Food, FDA, VPS, Dementia, Pharmaceutical industry

NEW YORK, April 4, 2024 /PRNewswire/ -- QuantalX Neuroscience, a pioneering healthcare company dedicated to early detection of brain disorders using the Delphi-MD medical device, announced today its selection to participate in the highly prestigious Total Life Cycle Advisory Program (TAP) initiated by the U.S. Food and Drug Administration (FDA). The program will focus on advancing Delphi-MD's unique Direct Electrophysiology Imaging technology, enabling the early detection of Normal Pressure Hydrocephalus (NPH) disease, with high accuracy rates, and the prediction of patients' response to ventriculoperitoneal shunting (VPS). The TAP program brings together the FDA, major health insurers, healthcare organizations, and industry leaders in a collaborative effort to construct a comprehensive strategy for technologies that can benefit the general population. This strategic framework spans crucial elements, such as value creation in the U.S. market, meticulous preparation for regulatory approval, meaningful engagement with insurers, and the establishment of a robust market presence with customers.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire/ -- QuantalX Neuroscience, a pioneering healthcare company dedicated to early detection of brain disorders using the Delphi-MD medical device, announced today its selection to participate in the highly prestigious Total Life Cycle Advisory Program (TAP) initiated by the U.S. Food and Drug Administration (FDA).
  • "The acceptance into the Total Life Cycle Advisory Program is a truly prestigious and significant opportunity for QuantalX," remarked Iftach Dolev.
  • The Total Life Cycle Advisory Program aims to guide innovative technologies through the entire product life cycle, ensuring regulatory compliance, market adoption, and enhanced positive patient impact.
  • The valuable experience and insights within this program are expected to accelerate QuantalX's market entry and establish a solid foundation for future growth.

TSC Alliance® to Host 23rd Annual Comedy for a Cure® on April 14 in Los Angeles

Retrieved on: 
金曜日, 3月 15, 2024
TSC, Jim, Learning, Parks and Recreation, Disease, Patient, The King of Queens, Neoplasm, DSM-IV codes, Research, Courage, Vibiana, The Tonight Show, Ovation, Movement disorder, Jazz, Jazz Pharmaceuticals, Comedy, Cure, Pharmaceutical industry

LOS ANGELES, March 15, 2024 /PRNewswire/ -- Today, the TSC Alliance ® announced its 23nd Annual Comedy for a Cure ® will be held Sunday, April 14, at the historic Vibiana in Los Angeles.

Key Points: 
  • LOS ANGELES, March 15, 2024 /PRNewswire/ -- Today, the TSC Alliance ® announced its 23nd Annual Comedy for a Cure ® will be held Sunday, April 14, at the historic Vibiana in Los Angeles.
  • "Every year, Comedy for Cure helps our organization raise significant funds to further TSC research, offer expanded support programs and increase awareness about the disease," said Kari Luther Rosbeck, TSC Alliance President & CEO.
  • "Over the years, this signature event has raised almost $6 million cumulatively to help improve the lives of everyone affected by TSC."
  • Comedy for a Cure also offers the opportunity to pay tribute to those who have made significant impacts in the right against TSC.

Withdrawn application: Ongentys, 12/03/2024

Retrieved on: 
水曜日, 4月 3, 2024
Dopamine, DDCI, Brain, Letter, Capsule, Myenteric plexus, L-DOPA, Patient, Movement disorder, European Medicines Agency, Clinical trial, Mouth, MDS, Delayed onset muscle soreness, Movement, COMT, MDS-UPDRS, Medicine, Pharmaceutical industry

Fluctuations happen when the effects of the medication wear off and symptoms re-emerge before the next dose is due.

Key Points: 
  • Fluctuations happen when the effects of the medication wear off and symptoms re-emerge before the next dose is due.
  • It contains the active substance opicapone and is available as capsules to be taken by mouth.
  • t
    The application was withdrawn after the European Medicines Agency had evaluated the information from the company and had prepared questions for the company.
  • If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.